Clinical Trial Insights

Executive Director and Professor, Tufts University School of Medicine

Articles

Self-determined eligibility and the influence of clinical care challenge this flawed figure.

Rebooting the Statistic That 5% of Eligible Patients Participate in Clinical Trials 

The struggle to translate promising movements in R&D.

Contemplating a Pressing Drug Development Paradox 

AI presents rare opportunity to assess the scope of this longtime challenge. 

Taking Stock of Intentional Dose Non-Adherence

Study holds new benchmarks and improvement opportunities.

Untapped Opportunity to Improve the Vendor Qualification Process

Kenneth Getz is a senior research fellow at the Tufts Center for the Study of Drug Development.

Record numbers point to new R&D operating environment, driven by a changing community of sponsors.

Reveling in 2018's Revealing Drug and Biologic Approvals

It’s time to establish standard practices to return clinical trial results summaries to patients.

Getting Serious About Plain Language Transparency

New study reveals that inconsistent, tactical, and reactive outsourcing practices predominate.

Insights into Outsourcing Practices and Oversight Effectiveness

Reexamining traditional cycle-time reduction strategies is critical for sponsors, CROs, and sites.

Placing a Premium on Informed Upfront Planning

Amid industry feedback that the growing volume and diversity of eClinical data collected for studies is taxing cycle times, two studies highlight the need to optimize protocol design and executional complexity to overcome these data management burdens. 

Surmounting eClinical Data Volume and Diversity

Study examines the growing integration of real-world data and evidence and the remaining roadblocks to adoption.    